Clinical trial NCT04306471: Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)
Official title: Effect of Evolocumab in Patients With Critical Limb Ischemia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Critical Limb Ischemia
Keywords: CLI, Gangrene, Ischemia, Amputation
Lead sponsor: University of Southern California
Sponsor class: OTHER
Collaborators: name: Amgen
First posted: 2020-03-13
Enrollment: 32
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a double-blinded, prospective, randomized, pilot, study
Primary purpose: TREATMENT

Brief summary: Critical limb ischemia (CLI), is the most severe form of peripheral arterial disease (PAD), and clinically is characterized by pain at rest or non-healing ulcers of the lower extremities. Also, is associated with increased risk of cardiovascular death, myocardial infarction (MI), stroke and amputation.

Feringa et al. demonstrated in a study of 1,374 patients with PAD that all cause and cardiac related mortality rates were lower in patients at higher statin dose and lower levels of low-density lipoprotein cholesterol (LDL).

Patients with CLI statin therapy and lower LDL levels improve amputation-free survival and patency after revascularization procedures.

In the FOURIER trial, LDL cholesterol reduction with the PCSK9 inhibitor evolocumab in patients with symptomatic PAD with or without prior myocardial infarction or stroke was associated with improved major adverse cardiac events (MACE) and major adverse limb events (MALE) at 2-years.

The effect of evolocumab in patients with CLI , after a recent arterial revascularization and active wounds is not known, also it is not known whether the cholesterol lowering effect of evolocumab in this group of patients is equivalent to that of non-CLI PAD patients and what the effect is on arterial perfusion, wound healing and other biological markers of vascular physiology.

This study aims to investigate the effect of evolocumab in patients with CLI on maximally tolerated lipid lowering therapy with a statin for one year after an index CLI event, requiring revascularization.

Detailed description: This is a double-blinded, prospective, randomized, pilot, study in thirty-two subjects with clinical CLI on background treatment with a statin. Subjects will be assessed based on their medical history and physical examination. Eligible subjects must meet all inclusion criteria and none of the exclusion criteria. There will be a treatment group and a placebo group, each with equal number of participants (n=16 patients in each group). After consent and enrollment, subjects will have a venous blood sample drawn to perform a lipid profile, serum vascular growth factors such as: vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1), soluble VEGF receptor-2 (sVEGFR-2), fibroblast growth factor (FGF), von Willebrand factor (vWF), tissue plasminogen activator (TPA) and plasminogen activator inhibitor -1 (PAI-1) and endothelial progenitor cells (EPCs). The investigators will then perform lower extremity arterial perfusion assessment of the affected and unaffected limb as rest ankle-brachial index (ABI), toe-brachial index (TBI), bilateral transcutaneous partial pressure of oxygen (TcPO2), spatial frequency domain imaging (SFDI), femoral studies (FMT, compliance, distensibility and stiffness), brachial endothelial function testing (FMD after hyperemia and maximal vasodilation). The study participant subjects will receive monthly subcutaneous injections of evolocumab 420 mg or placebo injections.

The LDL cholesterol will be measured at the baseline and a blinded measurement will also be performed at 3 and 12 months.

In patients with active wounds, healing will be evaluated at baseline and every month for six months by photographic analysis using planimetry and 2D/3D topographic analysis.

The study participants patients will be seen at 3, 6, and 9 months for follow up.

After 12 months +/- 2 weeks, all tests will be repeated.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent.
* Age ≥40 to ≤85 years of age at the time of consent.
* Diagnosis CLI, Rutherford class IV to VI at the time of diagnosis, toe pressure ≤30 mmHg in non-diabetics or ≤40 mmHg in diabetics, angiography, duplex ultrasound or history of lower extremity surgical or endovascular revascularization for CLI.
* Stable on maximal tolerated dose of a statin, defined as the highest dose of statin (preferably atorvastatin or rosuvastatin) tolerated by the patient without side effects for at least one month.

Exclusion Criteria:

* Less than 1 month from last revascularization procedure including surgery or endovascular procedures.
* Subjects with active infection.
* Diabetes therapy with canagliflozin
* Subjects who in the opinion of the Principal Investigator will likely require additional. amputation or revascularization procedures during the duration of the study.
* Subjects with anticipated need of cardiac or surgical revascularization procedures.
* Subjects with chronic inflammatory conditions or requiring chronic systemic corticosteroids.
* New York Heart Association (NYHA) class III or IV heart failure, or known left ventricular ejection fraction \<30%.
* Uncontrolled arrhythmia.
* Uncontrolled hypertension with systolic BP\>180 mmHg or diastolic \>100 mmHg.
* Untreated thyroid disease.
* Severe chronic renal disease with estimated glomerular filtration rate (eGFR) \<20 mL/min.
* Liver disease with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥3 times the upper limit of normal.
* Status post-organ transplant.
* Pregnant and breastfeeding women.
* Fertile age female not on appropriate birth control.
* Clinically significant disease that, in the opinion of the Principal Investigator, is likely to require surgery or immunotherapy that may interfere with the completion of the study.
* Active cancer or life expectancy of less than two years.
* Chronic anticoagulation or hypercoagulability disorder.
* Atrial fibrillation with a CHADS-VASc Score ≥2 or any clinical condition which, in the opinion of the Principal Investigator increases the risk of cerebrovascular events.

Primary outcomes:
measure: Evolocumab effect on LDL cholesterol changes in patients with Critical Limb Ischemia
timeFrame: 3 months
Secondary outcomes:
measure: Evolocumab effect on Lower extremity arterial perfusion changes on ankle-brachial indices (ABI).
timeFrame: 12 months
measure: Evolocumab effect on Lower extremity arterial perfusion pressure changes on toe-brachial indices (TBI).
timeFrame: 12 months
measure: Evolocumab effect on Lower extremity microvascular perfusion changes.
timeFrame: 12 months
measure: Evolocumab effect on foot perfusion changes.
timeFrame: 6 months
measure: Evolocumab effect on Femoral arterial distensibility changes.
timeFrame: 12 months
measure: Evolocumab effect on Femoral artery Medial Thickness (FMT) changes.
timeFrame: 12 months
measure: Evolocumab effect on endothelial function by Flow Mediated Dilation (FMD) changes.
timeFrame: 12 months
Other outcomes:
measure: Evolocumab effect on wound healing changes.
timeFrame: 6 months
measure: Evolocumab effect on serum levels of vascular endothelial growth factors changes.
timeFrame: 12 months
measure: Evolocumab effect on circulating endothelial progenitor cells changes
timeFrame: 12 months
Locations:
city: Los Angeles
country: United States
facility: University of Southern California
state: California
Study officials:
affiliation: University of Southern California
name: Leonardo Clavijo, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: